BICARA THERAPEUTICS INC (BCAX) — insider trading
Health Care · NASDAQ
BICARA THERAPEUTICS INC (BCAX) has 70 reported SEC Form 4 insider transactions in our data, including 24 open-market sales among the most recent 70 (latest 2026-09-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Cohlhepp Ryan | Director, Officer (President, COO & Interim CEO) | Option exercise / conversion (derivative) | 17,500 | — | $0 | Form 4 |
| 2026-09-08 | Cohlhepp Ryan | Director, Officer (President, COO & Interim CEO) | Open-market sale | 3,442 | $23.43 | $80.7K | Form 4 |
| 2026-09-08 | Cohlhepp Ryan | Director, Officer (President, COO & Interim CEO) | Open-market sale | 14,058 | $22.77 | $320.1K | Form 4 |
| 2026-09-08 | Cohlhepp Ryan | Director, Officer (President, COO & Interim CEO) | Option exercise / conversion | 17,500 | $3.79 | $66.3K | Form 4 |
| 2026-08-12 | Larson Jennifer | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 285,000 | — | $0 | Form 4 |
| 2026-08-10 | Cohlhepp Ryan | Director, Officer (President and COO) | Option exercise / conversion (derivative) | 18,750 | — | $0 | Form 4 |
| 2026-08-10 | Cohlhepp Ryan | Director, Officer (President and COO) | Open-market sale | 18,750 | $27.98 | $524.5K | Form 4 |
| 2026-08-10 | Cohlhepp Ryan | Director, Officer (President and COO) | Option exercise / conversion | 18,750 | $3.79 | $71.1K | Form 4 |
| 2026-08-10 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-08-10 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Open-market sale | 10,000 | $27.98 | $279.8K | Form 4 |
| 2026-08-10 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 10,000 | $3.79 | $37.9K | Form 4 |
| 2026-08-10 | Hyep Ivan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 12,500 | — | $0 | Form 4 |
| 2026-08-10 | Hyep Ivan | Officer (Chief Financial Officer) | Open-market sale | 12,500 | $27.97 | $349.6K | Form 4 |
| 2026-08-10 | Hyep Ivan | Officer (Chief Financial Officer) | Option exercise / conversion | 12,500 | $3.79 | $47.4K | Form 4 |
| 2026-07-28 | Oliger Christy J. | Director | Grant / award / vesting (derivative) | 38,950 | — | $0 | Form 4 |
| 2026-07-28 | Bender Jeremy | Director | Grant / award / vesting (derivative) | 38,950 | — | $0 | Form 4 |
| 2026-07-10 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-07-10 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Open-market sale | 28 | $29.68 | $831 | Form 4 |
| 2026-07-10 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Open-market sale | 9,972 | $28.42 | $283.4K | Form 4 |
| 2026-07-10 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 10,000 | $3.79 | $37.9K | Form 4 |
| 2026-07-09 | Cohlhepp Ryan | Director, Officer (President and COO) | Open-market sale | 536 | $29.00 | $15.5K | Form 4 |
| 2026-07-08 | Hyep Ivan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 908 | — | $0 | Form 4 |
| 2026-07-08 | Hyep Ivan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 11,592 | — | $0 | Form 4 |
| 2026-07-08 | Hyep Ivan | Officer (Chief Financial Officer) | Open-market sale | 830 | $30.31 | $25.2K | Form 4 |
| 2026-07-08 | Hyep Ivan | Officer (Chief Financial Officer) | Open-market sale | 4,413 | $29.82 | $131.6K | Form 4 |
| 2026-07-08 | Hyep Ivan | Officer (Chief Financial Officer) | Open-market sale | 22,757 | $28.60 | $650.9K | Form 4 |
| 2026-07-08 | Hyep Ivan | Officer (Chief Financial Officer) | Option exercise / conversion | 12,500 | $3.79 | $47.4K | Form 4 |
| 2026-07-08 | Cohlhepp Ryan | Director, Officer (President and COO) | Option exercise / conversion (derivative) | 18,750 | — | $0 | Form 4 |
| 2026-07-08 | Cohlhepp Ryan | Director, Officer (President and COO) | Open-market sale | 1,075 | $30.35 | $32.6K | Form 4 |
| 2026-07-08 | Cohlhepp Ryan | Director, Officer (President and COO) | Open-market sale | 4,306 | $29.80 | $128.3K | Form 4 |
| 2026-07-08 | Cohlhepp Ryan | Director, Officer (President and COO) | Open-market sale | 22,833 | $28.76 | $656.7K | Form 4 |
| 2026-07-08 | Cohlhepp Ryan | Director, Officer (President and COO) | Option exercise / conversion | 18,750 | $3.79 | $71.1K | Form 4 |
| 2026-06-09 | Simson Jake | Director | Grant / award / vesting (derivative) | 19,475 | — | $0 | Form 4 |
| 2026-06-09 | POWELL MICHAEL | Director | Grant / award / vesting (derivative) | 19,475 | — | $0 | Form 4 |
| 2026-06-09 | Robertson Scott M. | Director | Grant / award / vesting (derivative) | 19,475 | — | $0 | Form 4 |
| 2026-06-09 | Mazumdar-Shaw Kiran | Director | Grant / award / vesting (derivative) | 19,475 | — | $0 | Form 4 |
| 2026-06-09 | Haviland Kate | Director | Grant / award / vesting (derivative) | 19,475 | — | $0 | Form 4 |
| 2026-06-09 | Bowden Christopher | Director | Grant / award / vesting (derivative) | 19,475 | — | $0 | Form 4 |
| 2026-06-09 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 19,475 | — | $0 | Form 4 |
| 2026-05-21 | Hyep Ivan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 9,200 | — | $0 | Form 4 |
| 2026-05-21 | Hyep Ivan | Officer (Chief Financial Officer) | Open-market sale | 9,200 | $20.42 | $187.9K | Form 4 |
| 2026-05-21 | Hyep Ivan | Officer (Chief Financial Officer) | Option exercise / conversion | 9,200 | $3.79 | $34.9K | Form 4 |
| 2026-05-18 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-05-18 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Open-market sale | 2,978 | $20.35 | $60.6K | Form 4 |
| 2026-05-18 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Open-market sale | 12,022 | $19.96 | $240.0K | Form 4 |
| 2026-05-18 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 15,000 | $3.79 | $56.8K | Form 4 |
| 2026-05-15 | Cohlhepp Ryan | Director, Officer (President and COO) | Option exercise / conversion (derivative) | 8,000 | — | $0 | Form 4 |
| 2026-05-15 | Cohlhepp Ryan | Director, Officer (President and COO) | Open-market sale | 4,500 | $20.29 | $91.3K | Form 4 |
| 2026-05-15 | Cohlhepp Ryan | Director, Officer (President and COO) | Open-market sale | 8,000 | $20.29 | $162.3K | Form 4 |
| 2026-05-15 | Cohlhepp Ryan | Director, Officer (President and COO) | Option exercise / conversion | 8,000 | $3.79 | $30.3K | Form 4 |
| 2026-05-08 | Schelman William | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 85,000 | — | $0 | Form 4 |
| 2026-04-27 | Raben David | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 5,500 | — | $0 | Form 4 |
| 2026-04-27 | Raben David | Officer (Chief Medical Officer) | Open-market sale | 5,500 | $22.88 | $125.8K | Form 4 |
| 2026-04-27 | Raben David | Officer (Chief Medical Officer) | Option exercise / conversion | 5,500 | $3.79 | $20.8K | Form 4 |
| 2026-04-21 | Hyep Ivan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 9,200 | — | $0 | Form 4 |
| 2026-04-21 | Hyep Ivan | Officer (Chief Financial Officer) | Open-market sale | 9,200 | $23.00 | $211.6K | Form 4 |
| 2026-04-21 | Hyep Ivan | Officer (Chief Financial Officer) | Option exercise / conversion | 9,200 | $3.79 | $34.9K | Form 4 |
| 2026-04-20 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-04-20 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Open-market sale | 15,000 | $23.61 | $354.1K | Form 4 |
| 2026-04-20 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 15,000 | $3.79 | $56.8K | Form 4 |
| 2026-04-16 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 7,080 | — | $0 | Form 4 |
| 2026-04-16 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 7,454 | — | $0 | Form 4 |
| 2026-04-16 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 8,226 | — | $0 | Form 4 |
| 2026-04-16 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 7,080 | $5.45 | $38.6K | Form 4 |
| 2026-04-16 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 7,454 | $3.79 | $28.2K | Form 4 |
| 2026-04-16 | Mazumdar Claire | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 8,226 | $4.44 | $36.5K | Form 4 |
| 2026-04-15 | Cohlhepp Ryan | Director, Officer (President and COO) | Option exercise / conversion (derivative) | 8,000 | — | $0 | Form 4 |
| 2026-04-15 | Cohlhepp Ryan | Director, Officer (President and COO) | Open-market sale | 4,500 | $23.01 | $103.5K | Form 4 |
| 2026-04-15 | Cohlhepp Ryan | Director, Officer (President and COO) | Open-market sale | 8,000 | $23.01 | $184.1K | Form 4 |
| 2026-04-15 | Cohlhepp Ryan | Director, Officer (President and COO) | Option exercise / conversion | 8,000 | $3.79 | $30.3K | Form 4 |
Ask the chat about BCAX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: BICARA THERAPEUTICS INC (BCAX).
Last updated 2026-09-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.